- Home
- MCRB
as 10-04-2024 4:00pm EST
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 142.0M | IPO Year: | 2015 |
| Target Price: | $4.17 | AVG Volume (30 days): | 5.4M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.17 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.54 - $2.06 | Next Earning Date: | 10-31-2024 |
| Revenue: | $374,000 | Revenue Growth: | -99.71% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Seres Therapeutics Inc. (MCRB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Young Teresa L. | MCRB | See Remarks | Aug 15 '24 | Sell | $0.84 | 728 | $611.52 | 80,106 | |
| DesRosier Thomas | MCRB | Chief Legal Officer and EVP | Aug 15 '24 | Sell | $0.84 | 873 | $733.32 | 124,173 | |
| von Moltke Lisa | MCRB | See Remarks | Aug 15 '24 | Sell | $0.84 | 973 | $817.32 | 21,013 | |
| Ege David S. | MCRB | See Remarks | Aug 15 '24 | Sell | $0.84 | 1,128 | $947.52 | 77,575 | |
| Shaff Eric D. | MCRB | CEO and President | Aug 15 '24 | Sell | $0.84 | 2,518 | $2,115.12 | 145,993 | |
| Henn Matthew R. | MCRB | See Remarks | Aug 15 '24 | Sell | $0.84 | 923 | $775.32 | 67,247 | |
| Young Teresa L. | MCRB | See Remarks | Aug 3 '24 | Sell | $1.08 | 24,480 | $26,533.87 | 80,106 |
Latest Seres Therapeutics Inc. News
MCRB Breaking Stock News: Dive into MCRB Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
Seres Therapeutics Files Registration for Resale of Shares by Societe des Produits Nestle
MT Newswires
5 days ago
Seres Therapeutics Completes Sale of VOWST Unit to Societe des Produits Nestle
GlobeNewswire
5 days ago
Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A
MT Newswires
9 days ago
Seres Therapeutics Shareholders Approve Sale of VOWST Unit to Nestle; Shares Rise
GlobeNewswire
9 days ago
Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30
GlobeNewswire
22 days ago
Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference
GlobeNewswire
23 days ago
Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
Zacks
a month ago
After Plunging -22.45% in 4 Weeks, Here's Why the Trend Might Reverse for Seres Therapeutics (MCRB)
Compare MCRB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MCRB Seres Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.